Search

Your search keyword '"Ulasi, Ifeoma I."' showing total 39 results
Start Over Author "Ulasi, Ifeoma I."
39 results on '"Ulasi, Ifeoma I."'

3. Cardiovascular Risk Factor Burden and Association With CKD in Ghana and Nigeria

Author

Olanrewaju, Timothy O., Osafo, Charlotte, Raji, Yemi R., Mamven, Manmak, Ajayi, Samuel, Ilori, Titilayo O., Arogundade, Fatiu A., Ulasi, Ifeoma I., Gbadegesin, Rasheed, Parekh, Rulan S., Tayo, Bamidele, Adeyemo, Adebowale A., Adedoyin, Olanrewaju T., Chijioke, Adindu A., Bewaji, Clement, Grobbee, Diederick E., Blankestijn, Peter J., Klipstein-Grobusch, Kerstin, Salako, Babatunde L., Adu, Dwomoa, and Ojo, Akinlolu O.

Published
2023
Full Text
View/download PDF

5. Capacity for the management of kidney failure in the International Society of Nephrology Africa region: report from the 2023 ISN Global Kidney Atlas (ISN-GKHA)

Author

Tannor, Elliot Koranteng, Davidson, Bianca, Nlandu, Yannick, Bagasha, Peace, Bilchut, Workagegnehu Hailu, Davids, M. Razeen, Diongole, Hassane M., Ekrikpo, Udeme E., Hafiz, Ehab O.A., Ibrahim, Kwaifa Salihu, Kalyesubula, Robert, Nalado, Aisha M., Olanrewaju, Timothy O., Onu, Ugochi Chika, Pereira-Kamath, Nikhil, Sakajiki, Aminu Muhammad, Salah, Mohamed, Vincent, Lloyd, Arruebo, Silvia, Bello, Aminu K., Caskey, Fergus J., Damster, Sandrine, Donner, Jo-Ann, Jha, Vivekanand, Johnson, David W., Levin, Adeera, Malik, Charu, Nangaku, Masaomi, Okpechi, Ikechi G., Tonelli, Marcello, Ye, Feng, Ashuntantang, Gloria Enow, Arogundade, Fatiu Abiola, Gawad, Mohammed Abdel, Abderrahim, Ezzedine, Akl, Ahmed, Amekoudi, Eyram Makafui Yoan, Amouzegar, Atefeh, Awobusuyi, Jacob Olugbenga, Bakoush, Omran, Chissico, Elsa R., Cho, Yeoungjee, Coker, Joshua, Cullis, Brett, Dahwa, Rumbidzai, Darwish, Rasha Ahmed, Davison, Sara N., Divyaveer, Smita, Ethier, Isabelle, Fagoonee, Kevin, Fofana, Aboubacar Sidiki, Freercks, Robert, Wing-Shing Fung, Winston, Gandzali-Ngabe, Pierre Eric, Ghimire, Anukul, Gouda, Zaghloul Elsafy, Habyarimana, Oswald, Htay, Htay, Wan, Davy Ip Min, Irish, Georgina, Ismail, Wesam, Jagne, Abubacarr, Jarraya, Faiçal, Jindal, Kailash, Kabllo, Babikir G., Kalebi, Ahmed Y., Kaze Folefack, François F., Kelly, Dearbhla M., Lalji, Rowena, Lomatayo, Ben, Mah, Sidi Mohamed, Zalba Mahamat Abderraman, Guillaume, McCulloch, Mignon, Mengistu, Yewondwossen Tadesse, Moloi, Mothusi Walter, Mwaba, Chisambo, Neuen, Brendon L., Ngigi, John, Niang, Abdou, Nyandwi, Joseph, Odeh, Emad, Osman, Mohamed A., Le Grand Ouanekpone, Cédric Patrick, Petrova, Anna, Ranivoharisoa, Eliane M., Riaz, Parnian, Saad, Syed, See, Emily, Sokwala, Ahmed, Solarin, Adaobi Uzoamaka, Sozio, Stephen M., Houssani, Tarik Sqalli, Kiswaya, Ernest Sumaili, Tia, Weu Melanie, Tiv, Sophanny, Ts'enoli, Thabang, Tungsanga, Somkanya, Ulasi, Ifeoma I., Vanglist, Ssentamu John, Viecelli, Andrea, Wadee, Shoyab, Wainstein, Marina, Wearne, Nicola, Yeung, Emily K., and Zaidi, Deenaz

Abstract

The burden of chronic kidney disease and associated risk of kidney failure are increasing in Africa. The management of people with chronic kidney disease is fraught with numerous challenges because of limitations in health systems and infrastructures for care delivery. From the third iteration of the International Society of Nephrology Global Kidney Health Atlas, we describe the status of kidney care in the ISN Africa region using the World Health Organization building blocks for health systems. We identified limited government health spending, which in turn led to increased out-of-pocket costs for people with kidney disease at the point of service delivery. The health care workforce across Africa was suboptimal and further challenged by the exodus of trained health care workers out of the continent. Medical products, technologies, and services for the management of people with nondialysis chronic kidney disease and for kidney replacement therapy were scarce due to limitations in health infrastructure, which was inequitably distributed. There were few kidney registries and advocacy groups championing kidney disease management in Africa compared with the rest of the world. Strategies for ensuring improved kidney care in Africa include focusing on chronic kidney disease prevention and early detection, improving the effectiveness of the available health care workforce (e.g., multidisciplinary teams, task substitution, and telemedicine), augmenting kidney care financing, providing quality, up-to-date health information data, and improving the accessibility, affordability, and delivery of quality treatment (kidney replacement therapy or conservative kidney management) for all people living with kidney failure.

Published
2024
Full Text
View/download PDF

7. Cardiovascular Risk Factor Burden and Association With CKD in Ghana and Nigeria

Author

Olanrewaju, Timothy O., primary, Osafo, Charlotte, additional, Raji, Yemi R., additional, Mamven, Manmak, additional, Ajayi, Samuel, additional, Ilori, Titilayo O., additional, Arogundade, Fatiu A., additional, Ulasi, Ifeoma I., additional, Gbadegesin, Rasheed, additional, Parekh, Rulan S., additional, Tayo, Bamidele, additional, Adeyemo, Adebowale A., additional, Adedoyin, Olanrewaju T., additional, Chijioke, Adindu A., additional, Bewaji, Clement, additional, Grobbee, Diederick E., additional, Blankestijn, Peter J., additional, Klipstein-Grobusch, Kerstin, additional, Salako, Babatunde L., additional, Adu, Dwomoa, additional, and Ojo, Akinlolu O., additional

Published
2022
Full Text
View/download PDF

8. Systematic review of international studies evaluating MDRD and CKD-EPI estimated glomerular filtration rate (eGFR) equations in Black adults

Author

Umeukeje, Ebele M., primary, Koonce, Taneya Y., additional, Kusnoor, Sheila V., additional, Ulasi, Ifeoma I., additional, Kostelanetz, Sophia, additional, Williams, Annette M., additional, Blasingame, Mallory N., additional, Epelbaum, Marcia I., additional, Giuse, Dario A., additional, Apple, Annie N., additional, Kaur, Karampreet, additional, González Peña, Tavia, additional, Barry, Danika, additional, Eisenstein, Leo G., additional, Nutt, Cameron T., additional, and Giuse, Nunzia B., additional

Published
2022
Full Text
View/download PDF

9. Implementation of a Non-Invasive Helmet Ventilation Solution for the Management of Severe COVID-19 Respiratory Disease in Nigeria: The CircumVent Project

Author

Ahonkhai, Aima A., primary, Abdu, Aliyu, additional, Adekanmbi, Olukemi, additional, Ajayi, Nnennaya A., additional, Ajayi, Samuel, additional, Akpobi, Happy, additional, Akpochafo, Ejiro Benjamin, additional, Aliyu, Muktar H., additional, Ayuk, Adaeze C, additional, Dada, Adedamola A., additional, Ezechi, Oliver C., additional, Falade, Catherine O., additional, Horstein, Alex, additional, Olusola, Idowu, additional, Idigbe, Ifeoma, additional, Mogaj, Sunday, additional, Morenikeji, Aleem A., additional, Musa, Baba M., additional, Nwosu, Nnamdi I., additional, Odewabi, Adenike A, additional, Ofokotun, Igho, additional, Ogedegbe, Gbenga, additional, Ogueh, Onome, additional, Oyewole, Temitope O, additional, Sotannde, Adeshola I., additional, Steinbach, Alan B., additional, Ulasi, Ifeoma I., additional, Ukwaj, Kingsley N., additional, Unigwe, Uchechukwu S., additional, Usman, Olagoke A., additional, Uzoke, Cyril, additional, Musa, Adesola Z., additional, Rotimi, Muyiwa K., additional, Akase, Iorhen E., additional, Adeyemo, Wasiu L., additional, Fenton, André A., additional, and Salako, Babatunde L., additional

Published
2022
Full Text
View/download PDF

13. International consensus definitions of clinical trial outcomes for kidney failure: 2020

Author

Anand, Shuchi, Argent, Nicholas, Babak, Elena, Banerjee, Debasish, Barratt, Jonathan, Bello, Aminu K., Bernardo, Angelito A., Blais, Jaime, Canovatchel, William, Caskey, Fergus J., Coresh, Josef, de Boer, Ian H., Eckardt, Kai-Uwe, Evans, Rhys DR., Feldman, Harold I., Fogo, Agnes B., Gudmundsdottir, Hrefna, Hamano, Takayuki, Harris, David C.H., Hauske, Sibylle J., Haynes, Richard, Herzog, Charles A., Hiemstra, Thomas, Idorn, Thomas, Inker, Lesley, Ishida, Julie H., Johnson, David W., Jones-Burton, Charlotte, Joseph, Amer, Koitka-Weber, Audrey, Kretzler, Matthias, Lawatscheck, Robert, Liew, Adrian, Moist, Louise, Naicker, Saraladevi, Nakashima, Reiko, Patel, Uptal, Filho, Roberto Pecoits, Rose, Jennifer B., Rosenberg, Noah L., Sinsakul, Marvin, Smoyer, William E., Sola, Laura, Sood, Amy R., Stengel, Benedicte, Taal, Maarten W., Tanaka, Mototsugu, Tonelli, Marcello, Tong, Allison, Toto, Robert, Trask, Michele, Ulasi, Ifeoma I., Wanner, Christoph, Wheeler, David C., Wolthers, Benjamin O., Wright, Harold M., Yamada, Yoshihisa, Zakharova, Elena, Levin, Adeera, Agarwal, Rajiv, Herrington, William G., Heerspink, Hiddo L., Mann, Johannes F.E., Shahinfar, Shahnaz, Tuttle, Katherine R., Donner, Jo-Ann, Jha, Vivekanand, Nangaku, Masaomi, de Zeeuw, Dick, Jardine, Meg J., Mahaffey, Kenneth W., Thompson, Aliza M., Beaucage, Mary, Chong, Kate, Roberts, Glenda V., Sunwold, Duane, Vorster, Hans, Warren, Madeleine, Damster, Sandrine, Malik, Charu, and Perkovic, Vlado

Published
2020
Full Text
View/download PDF

14. International consensus definitions of clinical trial outcomes for kidney failure: 2020

Author

Levin, Adeera, primary, Agarwal, Rajiv, additional, Herrington, William G., additional, Heerspink, Hiddo L., additional, Mann, Johannes F.E., additional, Shahinfar, Shahnaz, additional, Tuttle, Katherine R., additional, Donner, Jo-Ann, additional, Jha, Vivekanand, additional, Nangaku, Masaomi, additional, de Zeeuw, Dick, additional, Jardine, Meg J., additional, Mahaffey, Kenneth W., additional, Thompson, Aliza M., additional, Beaucage, Mary, additional, Chong, Kate, additional, Roberts, Glenda V., additional, Sunwold, Duane, additional, Vorster, Hans, additional, Warren, Madeleine, additional, Damster, Sandrine, additional, Malik, Charu, additional, Perkovic, Vlado, additional, Anand, Shuchi, additional, Argent, Nicholas, additional, Babak, Elena, additional, Banerjee, Debasish, additional, Barratt, Jonathan, additional, Bello, Aminu K., additional, Bernardo, Angelito A., additional, Blais, Jaime, additional, Canovatchel, William, additional, Caskey, Fergus J., additional, Coresh, Josef, additional, de Boer, Ian H., additional, Eckardt, Kai-Uwe, additional, Evans, Rhys DR., additional, Feldman, Harold I., additional, Fogo, Agnes B., additional, Gudmundsdottir, Hrefna, additional, Hamano, Takayuki, additional, Harris, David C.H., additional, Hauske, Sibylle J., additional, Haynes, Richard, additional, Herzog, Charles A., additional, Hiemstra, Thomas, additional, Idorn, Thomas, additional, Inker, Lesley, additional, Ishida, Julie H., additional, Johnson, David W., additional, Jones-Burton, Charlotte, additional, Joseph, Amer, additional, Koitka-Weber, Audrey, additional, Kretzler, Matthias, additional, Lawatscheck, Robert, additional, Liew, Adrian, additional, Moist, Louise, additional, Naicker, Saraladevi, additional, Nakashima, Reiko, additional, Patel, Uptal, additional, Filho, Roberto Pecoits, additional, Rose, Jennifer B., additional, Rosenberg, Noah L., additional, Sinsakul, Marvin, additional, Smoyer, William E., additional, Sola, Laura, additional, Sood, Amy R., additional, Stengel, Benedicte, additional, Taal, Maarten W., additional, Tanaka, Mototsugu, additional, Tonelli, Marcello, additional, Tong, Allison, additional, Toto, Robert, additional, Trask, Michele, additional, Ulasi, Ifeoma I., additional, Wanner, Christoph, additional, Wheeler, David C., additional, Wolthers, Benjamin O., additional, Wright, Harold M., additional, Yamada, Yoshihisa, additional, and Zakharova, Elena, additional

Published
2020
Full Text
View/download PDF

16. Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients

Author

Odili Augustine N, Ezeala-Adikaibe Birinus, Ndiaye Mouhamadou B, Anisiuba Benedict C, Kamdem Marius M, Ijoma Chinwuba K, Kaptue Joseph, Boombhi Hilaire J, Kolo Philip M, Shu Elvis N, Thijs Lutgarde, Staessen Jan A, Omotoso Babatunde A, Kingue Samuel, Ba Serigne A, Lemogoum Daniel, M’Buyamba-Kabangu Jean-René, and Ulasi Ifeoma I

Subjects
Antihypertensive therapy, Health policy and outcome research, Randomized clinical trial, Special populations, Medicine (General), R5-920
Abstract

Abstract Background The epidemic surge in hypertension in sub-Saharan Africa is not matched by clinical trials of antihypertensive agents in Black patients recruited in this area of the world. We mounted the Newer versus Older Antihypertensive agents in African Hypertensive patients (NOAAH) trial to compare, in native African patients, a single-pill combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic. Methods Patients aged 30 to 69 years with uncomplicated hypertension (140 to 179/90 to 109 mmHg) and ≤2 associated risk factors are eligible. After a four week run-in period off treatment, 180 patients have to be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg (R) or amlodipine/valsartan 5/160 mg (E). To attain blood pressure Results At the time of writing of this progress report, of 206 patients enrolled in the run-in period, 140 had been randomized. At randomization, the R and E groups were similar (P ≥ 0.11) with respect to mean age (50.7 years), body mass index (28.2 kg/m2), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and treatment naïve patients (72.7%). After randomization, in the R and E groups combined, blood pressure dropped by 18.2/10.1 mmHg, 19.4/11.2 mmHg, 22.4/12.2 mmHg and 25.8/15.2 mmHg at weeks two (n = 122), four (n = 109), eight (n = 57), and 12 (n = 49), respectively. The control rate was >65% already at two weeks. At 12 weeks, 12 patients (24.5%) had progressed to the higher dose of R or E and/or had α-methyldopa added. Cohort analyses of 49 patients up to 12 weeks were confirmatory. Only two patients dropped out of the study. Conclusions NOAAH (NCT01030458) demonstrated that blood pressure control can be achieved fast in Black patients born and living in Africa with a simple regimen consisting of a single-pill combination of two antihypertensive agents. NOAAH proves that randomized clinical trials of cardiovascular drugs in the indigenous populations of sub-Saharan Africa are feasible.

Published
2012
Full Text
View/download PDF

17. A community-based study of hypertension and cardio-metabolic syndrome in semi-urban and rural communities in Nigeria

Author

Onodugo Obinna D, Ijoma Chinwuba K, and Ulasi Ifeoma I

Subjects
Public aspects of medicine, RA1-1270
Abstract

Abstract Background The prevalence of cardio-metabolic syndrome (CMS) is increasing worldwide. In people of African descent, there is higher prevalence of hypertension and complications than other races. Bearing in mind these facts, we looked at the CMS in the general population and the population with hypertension. Using the new International Diabetes Federation (IDF) definitions of CMS, we studied its prevalence in semi-urban and rural communities in South-east Nigeria in relation to hypertension. Method This is a cross sectional population based study involving 1458 adults aged from 25 to 64 years. Diagnosis of CMS was based on the new IDF criteria using the anthropometric measurements for Europids as there is none yet for blacks. Hypertension was defined according to the WHO/ISH criteria. Results The overall prevalence of CMS was 18.0% in the semi-urban community as against 10.0% in the rural community increasing to 34.7% and 24.7% respectively in the population with hypertension. The prevalence of co-morbidities - hyperglycaemia, abdominal obesity, and hypertriglceridaemia were 13.9%, 41.1% and 23.9% while in the hypertensive populations they were 21.2%, 55.0% and 31.3% in the general population in both communities combined. Except for low HDL cholesterol, every other co-morbidity was higher in hypertensive population than the general population. Conclusion The high prevalence of CMS in the semi-urban population especially for the population with hypertension underscores the double burden of disease in developing countries. The lesson is while infections and infestations are being tackled in these countries the non-communicable diseases should not be neglected.

Published
2010
Full Text
View/download PDF

19. Heart rate variability on antihypertensive drugs in black patients living in sub-Saharan Africa

Author

Osakwe, Chukwunomso E, Jacobs, Lotte, Anisiuba, Benedict C, Ndiaye, Mouhamado B, Lemogoum, Daniel, Ijoma, Chinwuba K, Kamdem, Marius M, Thijs, Lutgarde, Boombhi, Hilaire J, Kaptue, Joseph, Kolo, Philip M, Mipinda, Jean B, Odili, Augustine N, Ezeala-Adikaibe, Birinus, Kingue, Samuel, Omotoso, Babatunde A, Ba, Serigne A, Ulasi, Ifeoma I, M'buyamba-Kabangu, Jean-Rene, Staessen, Jan A, On behalf of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients Trial (NOAAH) Investigators, Epidemiologie, and RS: CARIM - R3 - Vascular biology

Subjects
Male, sub-Saharan Africa, medicine.medical_specialty, Cohort Studies, Hydrochlorothiazide, Heart Rate, Internal medicine, Heart rate, Internal Medicine, medicine, Heart rate variability, Humans, Amlodipine, Antihypertensive drugs, Africa South of the Sahara, Antihypertensive Agents, Traditional medicine, business.industry, heart rate variability, General Medicine, Middle Aged, medicine.disease, blacks, randomized clinical trial, 3. Good health, Blood pressure, Valsartan, Bisoprolol, Hypertension, Cardiology, Arterial stiffness, Original Article, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background. Compared with Caucasians, African Americans have lower heart rate variability (HRV) in the high-frequency domain, but there are no studies in Blacks born and living in Africa. Methods. In the Newer versus Older Antihypertensive agents in African Hypertensive patients trial (NCT01030458), patients (30-69 years) with uncomplicated hypertension (140-179/90-109 mmHg) were randomized to single-pill combinations of bisoprolol/hydrochlorothiazide (R) or amlodipine/valsartan (E). 72 R and 84 E patients underwent 5-min ECG recordings at randomization and 8, 16 and 24 weeks. HRV was determined by fast Fourier transform and autoregressive modelling. Results. Heart rate decreased by 9.5 beats/min in R patients with no change in E patients (- 2.2 beats/min). R patients had reduced total (- 0.13 ms²; p = 0.0038) and low-frequency power (- 3.6 nu; p = 0.057), higher high-frequency (+ 3.3 nu; p = 0.050) and a reduced low- to high-frequency ratio (- 0.08; p = 0.040). With adjustment for heart rate, these differences disappeared, except for the reduced low-frequency power in the R group (- 4.67 nu; p = 0.02). Analyses confined to 39 R and 47 E patients with HRV measurements at all visits or based on autoregressive modelling were confirmatory. Conclusion. In native Black African patients, antihypertensive drugs modulate HRV, an index of autonomous nervous tone. However, these effects were mediated by changes in heart rate except for low-frequency variability, which was reduced on beta blockade independent of heart rate. peerreview_statement: The publishing and review policy for this title is described in its Aims & Scope. aims_and_scope_url: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iblo20 ispartof: Blood Pressure vol:23 issue:3 pages:174-80 ispartof: location:England status: published

Published
2014

20. Neglected and Emerging Infections of The Kidney

Author

Ulasi, Ifeoma I., Burdmann, Emmanuel A., Ijoma, Chinwuba K., Chou, Li-Fang, and Yang, Chih-Wei

Abstract

Individuals, societies, and the environment are affected by neglected and emerging diseases. These diseases result in a variety of severe outcomes, including permanent disabilities, chronic diseases such as chronic kidney disease, and even mortality. Consequences include high health care expenditures, loss of means of support, social stigma, and social exclusion. The burden of these diseases is exacerbated in low- and middle-income countries owing to poverty, inadequate fundamental infrastructure, and the absence of health and social protection systems. The World Health Organization is committed to promoting the following public health strategies to prevent and control neglected tropical diseases: preventive chemotherapy; intensive case management; vector control; provision of safe drinkable water, sanitation, and hygiene; and veterinary public health. In addition, it promotes a One Health strategy, which is a collaborative, multisectoral, and interdisciplinary approach to achieving the greatest health outcomes by recognizing the interdependence of human beings, animals, plants, and their shared environment. This article provides knowledge and strategies for the prevention and treatment of neglected and emerging diseases, with a particular concentration on kidney diseases, as part of a comprehensive approach to One Health.

Published
2024
Full Text
View/download PDF

24. Lifestyle risk factors: do they contribute to chronic kidney disease in developing countries?

Author

Ulasi, Ifeoma I., Ijoma, Chinwuba K., Arodiwe, Ejikeme B., Okoye, Julius U., and Ifebunandu, Ngozi A.

Subjects
Chronic kidney failure -- Risk factors, Chronic kidney failure -- Development and progression, Chronic kidney failure -- Demographic aspects, Health
Abstract

Chronic kidney disease (CKD) is one of the world's major public health issues. Many people in developing-countries adopt unhealthy western lifestyle which predisposes them to non-communicable diseases. Though, chronic glomerulonephritis may be the leading cause of CKD in these countries, studies in some developing-countries document that lifestyle risk factors are emerging as important in CKD.In Nigeria, though CKD constitutes 8% of hospital admissions, there is no known population-based study on CKD. This study, an arm of a larger project on early detection of CKD in Nigeria, examined modifiable lifestyle risk factors in relation to markers of CKD., Introduction The burden and magnitude of chronic kidney disease (CKD) is enormous especially in developing countries. CKD currently is one of the world's major public health issues. Lifestyle related diseases [...]

Published
2010

25. Anaemia predicts prolonged QT interval in predialysis chronic kidney disease patients

Author

Ijoma, Chinwuba K., Ulasi, Ifeoma I., and Anisiuba, Benedict C.

Subjects
Chronic kidney failure -- Care and treatment, Chronic kidney failure -- Patient outcomes, Chronic kidney failure -- Research, Hemodialysis -- Patient outcomes, Hemodialysis -- Research, Long QT syndrome -- Diagnosis, Long QT syndrome -- Risk factors, Long QT syndrome -- Demographic aspects, Long QT syndrome -- Research, Health
Abstract

Background. Patients with advanced chronic kidney disease (CKD) have increased cardiovascular mortality of multifactorial aetiology including cardiac arrhythmias. Prolonged QT interval may be responsible for some of the cardiac deaths. This prospective cross sectional study investigated the QTc in predialysis chronic kidney disease patients compared with age and sex matched controls subjects. It also investigated association between QTc and variables that may affect it. Methods. Ninety one patients in CKD stages 3 to 5 and thirty two control subjects matched for age and sex were studied using standard 12-lead electrocardiogram. Results. Fifty four (59.3%) of CKD patients had abnormal QTc defined as QTc [greater than or equal to] 0.44. This was observed in all the stages of CKD studied (67% for CKD stage 3, 62% for stage 4 and 58% for stage 5). There was no statistical difference in the frequency of abnormal QTc between the stages of CKD, p = 0.707. All the control subjects had normal QTc with a mean of 0.38 [+ or -] 0.02. BMI, SBP, DBP, Hb, and aetiology of CKD correlated with QTc. Only Hb predicted the presence of prolonged QTc in CKD. Conclusion. The QTc interval is significantly prolonged in predialysis CKD patients in this study. This abnormality was present in stages 3 to 5 CKD. This may be a contributing factor to the high cardiovascular mortality in CKD patients. Anaemia was predictive of prolonged QTc in this study. It is reasonable to recommend an ECG as part of the evaluation of all patients with CKD. Keywords: QT interval | anaemia | chronic kidney disease, Introduction Patients with chronic kidney disease are at significantly increased risk for both morbidity and mortality from cardiovascular disease, (1,2). Cardiovascular disease accounts for at least 50% of deaths in [...]

Published
2010

26. Maximum accuracy obesity indices for screening metabolic syndrome in Nigeria: A consolidated analysis of four cross-sectional studies

Author

Oguoma, Victor M., primary, Nwose, Ezekiel U., additional, Ulasi, Ifeoma I., additional, Akintunde, Adeseye A., additional, Chukwukelu, Ekene E., additional, Araoye, Matthew A., additional, Edo, Andrew E., additional, Ijoma, Chinwuba K., additional, Onyia, Innocent C., additional, Ogbu, Innocent I., additional, Onyeanusi, Joel C., additional, Digban, Kester A., additional, Onodugo, Obinna D., additional, Adediran, Olufemi, additional, Opadijo, Oladimeji G., additional, Bwititi, Phillip T., additional, Richards, Ross S., additional, and Skinner, Timothy C., additional

Published
2016
Full Text
View/download PDF

28. High Population Frequencies of APOL1 Risk Variants Are Associated with Increased Prevalence of Non-Diabetic Chronic Kidney Disease in the Igbo People from South-Eastern Nigeria

Author

Ulasi, Ifeoma I., primary, Tzur, Shay, additional, Wasser, Walter G., additional, Shemer, Revital, additional, Kruzel, Etty, additional, Feigin, Elena, additional, Ijoma, Chinwuba K., additional, Onodugo, Obinna D., additional, Okoye, Julius U., additional, Arodiwe, Ejikeme B., additional, Ifebunandu, Ngozi A., additional, Chukwuka, Chinwe J., additional, Onyedum, Cajetan C., additional, Ijoma, Uchenna N., additional, Nna, Emmanuel, additional, Onuigbo, Macaulay, additional, Rosset, Saharon, additional, and Skorecki, Karl, additional

Published
2013
Full Text
View/download PDF

30. Chronic Kidney Disease Burden in low-resource settings: regional perspectives

Author

Ulasi, Ifeoma I., Awobusuyi, Olugbenga, Nayak, Saurabh, Ramachandran, Raja, Musso, Carlos G., Depine, Santos A., Aroca-Martinez, Gustavo, Solarin, Adaobi Uzoamaka, Onuigbo, Macaulay, Luyckx, Valerie A., and Ijoma, Chinwuba K

Abstract

Burden of chronic kidney disease has increased exponentially worldwide, but more so in low- and middle-income countries. Specific risk factors in these regions expose their populations to an increased risk of CKD, such as genetic risk with APOL1among populations of west African heritage or farmers with CKD of unknown etiology that spans various countries across several continents to immigrant/indigenous populations in both low and high-income countries. Low-and-middle-income economies also have the double burden of communicable and non-communicable diseases, both contributing to the high prevalence of CKD. The economies are characterized by low health expenditure, sparse or non-existent health insurance and welfare schemes and predominant out-of-pocket spending for medical care. This review highlights the challenges in populations with CKD from low-resource settings globally and explores how health systems can help ameliorate the CKD burden.

Published
2023
Full Text
View/download PDF

33. Central haemodynamics reveal significant potential for prevention in Black hypertensive patients born and living in sub-Saharan Africa

Author

Ezeala-Adikaibe, Birinus, primary, Liu, Yan-Ping, primary, Lemogoum, Daniel, primary, Anisiuba, Benedict C., primary, Kamdem, Marius K., primary, Kaptue, Joseph, primary, Ijoma, Chinwuba K., primary, Thijs, Lutgarde, primary, Odili, Augustine N., primary, Asayama, Kei, primary, Staessen, Jan A., primary, M’Buyamba-Kabangu, Jean-René, primary, and Ulasi, Ifeoma I., primary

Published
2011
Full Text
View/download PDF

37. Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.

Author

Odili, Augustine N., Richart, Tom, Thijs, Lutgarde, Kingue, Samuel, Boombhi, Hilaire J., Lemogoum, Daniel, Kaptue, Joseph, Kamdem, Marius K., Mipinda, Jean-Bruno, Omotoso, Babatunde A., Kolo, Philip M., Aderibigbe, Ademola, Ulasi, Ifeoma I., Anisiuba, Benedict C., Ijoma, Chinwuba K., Ba, Serigne A., Ndiaye, Mouhamadou B., Staessen, Jan A., and M'Buyamba-Kabangu, Jean-René

Subjects
THERAPEUTICS, HYPERTENSION, DIURETICS, ANTIHYPERTENSIVE agents, DOSE-effect relationship in pharmacology
Abstract

Background. Sub-Saharan Africa experiences an epidemic surge in hypertension. Studies in African Americans led to the recommendation to initiate antihypertensive treatment in Blacks with a diuretic or a low-dose fixed combination including a diuretic. We mounted the Newer versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial to compare in native African patients a fixed combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic. Methods. Patients aged 30-69 years with uncomplicated hypertension (140-179/90-109 mmHg) and two or fewer associated risk factors are eligible. After a 4-week run-in period off treatment, 180 patients will be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg or amlodipine/valsartan 5/160 mg. To attain and maintain blood pressure below 140/90 mmHg during 6 months of follow-up, the doses of bisoprolol and amlodipine in the combination tablets will be increased to 10 mg/day with the possible addition of α-methyldopa or hydralazine. NOAAH is powered to demonstrate a 5-mmHg between-group difference in sitting systolic pressure with a two-sided p-value of 0.01 and 90% power. NOAAH is investigator-led and complies with the Helsinki declaration. Results. Six centers in four sub-Saharan countries started patient recruitment on September 1, 2010. On December 1, 195 patients were screened, 171 were enrolled, and 51 were randomized and followed up. The trial will be completed in the third quarter of 2011. Conclusions. NOAAH (NCT01030458) is the first randomized multicenter trial of antihypertensive medications in hypertensive patients born and living in sub-Saharan Africa. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

38. Heart rate variability on antihypertensive drugs in Black patients living in sub-Saharan Africa

Author

Ezeala-adikaibe, Birinus, Kamdem, Marius M., Anisiuba, Benedict C., Jacobs, Lotte, Lemogoum, Daniel, Odili, Augustine N., Kingue, Samuel, Kaptue, Joseph, Ulasi, Ifeoma I., Boombhi, Hilaire J., Staessen, Jan A., Ndiaye, Mouhamado B., On behalf of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients Trial (NOAAH) Investigators, Ijoma, Chinwuba K., Kolo, Philip M., Ba, Serigne A., Osakwe, Chukwunomso E., Thijs, Lutgarde, M Buyamba-kabangu, Jean-rene, Mipinda, Jean B., and Omotoso, Babatunde A.

39. ENLARGED HEART FOUND IN NIGERIANS REPORTING WITH CHRONIC KIDNEY FAILURE.

Author

Ulasi, Ifeoma I., Arodiwe, Ejikeme B., and Ijoma, Chinwuba K.

Subjects
KIDNEY diseases, HEART dilatation, HEART diseases, HEART size, MEDICAL research
Abstract

The article highlights a study which focused on the prevalence of kidney disease and heart enlargement in Nigeria. According to the study, a strong link between long-standing kidney disease and heart enlargement does exist. The researchers recommend that early detection and treatment methods be followed aggressively as a preventive measure.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results